J0881Darbepoetin alfa, non-esrd
Published CMS Medicare Part B payment-limit context for J0881, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$2.92
per 1 MCG · Medicare Part B
Down 4.9%from $3.072 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$3.0936$2.8964
2024-Q4: $3.036; 2025-Q1: $2.972; 2025-Q2: $2.918; 2025-Q3: $2.995; 2025-Q4: $2.926; 2026-Q1: $3.021; 2026-Q2: $3.072; 2026-Q3: $2.92
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Darbepoetin Alfa ingredient family (FDA data as of August 20, 2026).
Aranesp
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Darbepoetin Alfa presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J0882 | Darbepoetin alfa, esrd use | $2.92 per 1 MCG | $3.072 per 1 MCG | Down 4.9% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.